Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Note: See sections 5 and 6.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2150	FABIANA IMBRICATA	A, H	
2151	FAGOPYRUM ESCULENTUM	A, H	
2152	FAGUS GRANDIFOLIA	A, H	
2153	FAGUS SYLVATICA	A, H	
2154	FALLOPIA MULTIFLORA	A, H	When for oral use, the medicine requires the following warning statement on the medicine label: - (FALLMUL) 'Warning: Fallopia multiflora may harm the liver in some people. Use under the supervision of a healthcare professional.'
2155	FARNESOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2156	FARNESYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%. When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
2157	FAST GREEN FCF	E	Permitted for use only as a colour for oral and topical use.
2158	FENCHONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2159	FENCHYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2160	FENCHYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2161	FENNEL BITTER SEED DRY	A, E, H	When used in oral medicines and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statements on the medicine label: - (CHILD3) ‘Use in children under 12 years is not recommended’ - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)' - (BREASF) 'Do not use while breastfeeding.' When used in oral medicines and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statements on the medicine label if supplied after 1 April 2019: - (CHILD3) ‘Use in children under 12 years is not recommended’ - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)' - (BREASF) 'Do not use while

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			breastfeeding.'
2162	FENNEL LEAF	E	
2163	FENNEL OIL	A, E, H	Methyl chavicol is a mandatory component of fennel oil. When the concentration of methyl chavicol in the medicine is more than 5%, the nominal capacity of the container must be no more than 25mL, a restricted flow insert must be fitted on the container, and the medicine requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children (or words to that effect).' The maximum daily dose must provide no more than 150 mg of fennel oil. When used in oral medicines and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statements on the medicine label: - (CHILD3) ‘Use in children under 12 years is not recommended.’ - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect).' - (BREASF) 'Do not use while breastfeeding.' When used in oral medicines and the medicine is listed in the

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			Register before 1 October 2017 the medicine requires the following statements on the medicine label if supplied after 1 April 2019: - (CHILD3) ‘Use in children under 12 years is not recommended.’ - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect).' - (BREASF) 'Do not use while breastfeeding.'
2164	FENNEL SWEET SEED DRY	A, E, H	When used in oral medicines and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statements on the medicine label: - (CHILD3) ‘Use in children under 12 years is not recommended’ - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)' - (BREASF) 'Do not use while breastfeeding.' When used in oral medicines and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statements on the medicine label if supplied after 1 April 2019: - (CHILD3) ‘Use in children under 12 years is not

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			recommended' - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)' - (BREASF) 'Do not use while breastfeeding.'
2165	FENUGREEK	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2166	FENUGREEK OIL	E	Fenugreek oil is permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2167	FERRIC AMMONIUM CITRATE	A, E, H	When for internal use, iron is a mandatory component of ferric ammonium citrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2168	FERRIC CHLORIDE	A, E, H	When for internal use, iron is a mandatory component of ferric chloride. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2169	FERRIC CHLORIDE HEXAHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferric chloride hexahydrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2170	FERRIC GLYCEROPHOSPHATE	A, E, H	When for internal use, iron is a mandatory component of ferric glycerophosphate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2171	FERRIC OXIDE	E	
2172	FERRIC PHOSPHATE	H	Only for use as an active

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			homoeopathic ingredient.
2173	FERRIC PYROPHOSPHATE	A, H	When for internal use, iron is a mandatory component of ferric pyrophosphate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2174	FERROSOFERRIC OXIDE	E	When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided preparations for internal use, the concentration in the medicine must be no more than 10 mg per dosage unit.
2175	FERROSOFERRIC PHOSPHATE	H	Only for use as an active homoeopathic ingredient.
2176	FERROUS FUMARATE	A, H	When for internal use, iron is a mandatory component of ferrous fumarate. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2177	FERROUS GLUCONATE	A, E, H	When for internal use, iron is a mandatory component of ferrous gluconate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2178	FERROUS GLUCONATE DIHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferrous gluconate dihydrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2179	FERROUS IODIDE	H	Only for use as an active homoeopathic ingredient.
2180	FERROUS LACTATE TRIHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferrous lactate trihydrate. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			resistant closure. Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2181	FERROUS PHOSPHATE OCTAHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferrous phosphate octahydrate. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			quantity of no more than 1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2182	FERROUS PICRATE	H	Only for use as an active homoeopathic ingredient.
2183	FERROUS SULFATE	A, E, H	When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2184	FERROUS SULFATE HEPTAHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferrous sulfate heptahydrate.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			treatment of iron deficiency conditions' (or words to that effect).
2185	FERULA ASSA-FOETIDA	A, E, H	
2186	FERULA FOETIDA	A, E, H	
2187	FERULA GALBANIFLUA	A, E, H	
2188	FERULA RUBRICAULIS	A, E, H	
2189	FERULA SUMBUL	A, H	
2190	FERULIC ACID	E	Only for use in topical medicines for dermal application.
2191	FESTUCA ELATIOR	A, H	
2192	FEVERFEW HERB DRY	A, H	
2193	FEVERFEW HERB POWDER	A, H	
2194	FICUS CARICA	A, E, H	
2195	FICUS PUMILA	A, H	
2196	FIG	E	
2197	FIG DRY	A, H	
2198	FILIPENDULA ULMARIA	A, H	Methyl salicylate is a mandatory component of Filipendula ulmaria. Not to be included in medicines for use in the eye or on damaged skin. When used internally, the concentration of methyl salicylate in the medicine must not be more than 0.001%. When the concentration of methyl salicylate in a liquid preparation is more than 5%

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			and the dosage form is other than spray, the medicine requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is spray, the medicine does not require child resistant packaging if: - the delivery device is engaged into the container in such a way that prevents it from being readily removed; - direct suction through the delivery device results in delivery of no more than one dosage unit; and - actuation of the spray device is ergonomically difficult for young children to accomplish. In addition, when the ingredient is included in a medicine that is listed in the Register: - on or after 1 July 2018, the medicine must comply with all requirements under (a) & (b); - before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a) & (b); or - before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with the requirements under (a) & (b). a) The following warning statement is required on the

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine label: - (METSAL) 'Contains methyl salicylate' (or words to that effect). b) When for use in topical medicines for dermal application, the concentration of methyl salicylate in the medicine must not be more than 25% and the following warning statements are required on the medicine label: - (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect); - (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less'; - (SENS) 'Application to skin may increase sensitivity to sunlight.' (or words to that effect); - (IRRIT) 'If irritation develops, discontinue use.'; and - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect).
2199	FIR BALSAM ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2200	FIR NEEDLE OIL CANADIAN	A, E	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2201	FIR NEEDLE OIL SIBERIAN	A, E	
2202	FIRMIANA SIMPLEX	A, E, H	
2203	FISH OIL - RICH IN OMEGA-3 ACIDS	A	Only for use in oral medicines.
2204	FLEMINGIA MACROPHYLLA	A, H	
2205	FLOUVE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2206	FLUORESCEIN SODIUM	E	
2207	FOENICULUM VULGARE	A, E, H	When used in oral medicines and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statements on the medicine label: - (CHILD3) ‘Use in children under 12 years is not recommended’ - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)' - (BREASF) 'Do not use while breastfeeding.' When used in oral medicines and the medicine is listed in the Register before 1 October 2017 the medicine requires the

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			following statements on the medicine label if supplied after 1 April 2019: - (CHILD3) ‘Use in children under 12 years is not recommended’ - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)' - (BREASF) 'Do not use while breastfeeding.' When the plant preparation is oil or distillate, methyl chavicol is a mandatory component and the maximum daily dose must provide no more than 150 mg of the plant preparation. When the plant preparation is oil or distillate and the concentration of methyl chavicol in the medicine is more than 5%, the nominal capacity of the container must be no more than 25mL, a restricted flow insert must fitted on the container, and the medicine requires the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
2208	FOLIC ACID	A	When for internal use, the maximum recommended daily dose must be no more than 500 micrograms of folic acid. When folic acid, folinic acid,

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			levomefolate salts and/or their derivatives are used in combination, the medicine must provide no more than a total of 500 micrograms of folic acid, folinic acid, levomefolate salts and/or their derivatives in total per daily dose. When used in preparations indicated for reducing the risk of having a child with spina bifida/neural tube defects: a) the maximum daily dose must provide 400 – 500 micrograms of folic acid; and b) the following statement must be included on the label: - (NEUR) 'Warning: Do not exceed the stated dose except on medical advice. If you have had a baby with a neural tube defect/spina bifida - seek specific medical advice (or words to that effect)'.
2209	FOOD ORANGE 6	E	Permitted for use only as a colour for oral and topical use.
2210	FOOD ORANGE 7	E	Permitted for use only as a colour for oral and topical use.
2211	FOOD RED 13	E	Permitted for use only as a colour for topical use.
2212	FORMALDEHYDE/MELAMINE/TOSYLAMIDE COPOLYMER	E	Only for use in topical medicines for dermal application.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			The concentration in the medicine must be no more than 10%.
2213	FORMIC ACID	H	Only for use as an active homoeopathic ingredient.
2214	FORSYTHIA SUSPENSA	A, H	
2215	FORTIFIED WINE	E	Ethanol is a mandatory component of fortified wine. When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label: - (ETHAN) 'Contains ethanol or contains alcohol'.
2216	FRACTIONATED COCONUT OIL	E	
2217	FRACTIONATED PALM KERNEL OIL	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
2218	FRAGARIA CHILOENSIS	A, E, H	
2219	FRAGARIA VESCA	A, E, H	
2220	FRAGARIA VIRGINIANA	A, E, H	
2221	FRAGARIA X ANANASSA	A, E, H	
2222	FRANGULA BARK DRY	A, H	Glucofrangulins calculated as glucofrangulin A is a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			mandatory component of Frangula bark dry. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX2) 'Prolonged use may cause serious bowel problems'; and - (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect]. When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label: - (LAX1) 'Drink plenty of water' [or words to that effect]. When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (LAX5) 'This product contains [name of the herb(s) or the chemical

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			component(s)]'; and - (LAX4) 'This product may have laxative effect'. When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX1) 'Drink plenty of water' [or words to that effect]; and - (LAX2) 'Prolonged use may cause serious bowel problems'.
2223	FRANGULA BARK POWDER	A, H	Glucofrangulins calculated as glucofrangulin A is a mandatory component of Frangula bark powder. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX2) 'Prolonged use may cause serious bowel problems'; and - (LAX3) 'Do not use when

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product [or words to that effect]'. When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label: - (LAX1) 'Drink plenty of water [or words to that effect]'. When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and - (LAX4) 'This product may have laxative effect'. When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX1) 'Drink plenty of water [or words to that effect]';

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			and - (LAX2) 'Prolonged use may cause serious bowel problems'.
2224	FRANGULA PURSHIANA	A, H	When for oral use, hydroxyanthracene derivatives calculated as cascaroside A is a mandatory component of Frangula purshiana. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX2) 'Prolonged use may cause serious bowel problems'; and - (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect]. When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label: - (LAX1) 'Drink plenty of water' [or words to that effect]. When not promoted or marketed as laxative, the

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine requires the following warning statements on the medicine label: - (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and - (LAX4) 'This product may have laxative effect'. When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX1) 'Drink plenty of water' [or words to that effect]; and - (LAX2) 'Prolonged use may cause serious bowel problems'.
2225	FRAXINUS AMERICANA	A, H	
2226	FRAXINUS CHINENSIS SUBSP. RHYNCHOPHYLLA	A, H	
2227	FRAXINUS EXCELSIOR	A, H	The components Nuzhenide and secoiridoid glucoside GL3 are only available when the plant part is seed.
2228	FRAXINUS ORNUS	A, H	
2229	FRITILLARIA CIRRHOSA	A, H	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2230	FRITILLARIA THUNBERGII	A, H	
2231	FRITILLARIA VERTICILLATA	A, H	
2232	FRUCTOOLIGOSACCHARIDES	A, E	
2233	FRUCTOSE	A, E, H	
2234	FUCUS VESICULOSUS	A, E, H	Iodine is a mandatory component of Fucus vesiculosus. Only for external use when the concentration of available iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2235	FUMARIA OFFICINALIS	A, E, H	
2236	FUMARIC ACID	E, H	Only for use as an active homoeopathic or excipient ingredient.
2237	FUMITORY HERB DRY	A, H	
2238	FUMITORY HERB POWDER	A, H	
2239	FURAMINTON	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2240	FURFURAL	E	Permitted for use only in

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2241	FURFURYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2242	FURFURYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2243	FURFURYL MERCAPTAN	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2244	FUSEL OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2245	GALBANUM OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2246	GALBANUM PHENOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2247	GALBANUM RESIN	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2248	GALBANUM RESINOID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2249	GALEGA OFFICINALIS	A, H	
2250	GALEOPSIS SEGETUM	A, H	
2251	GALIUM APARINE	A, H	
2252	GALIUM ODORATUM	A, H	When used as an active ingredient coumarin is a mandatory component of Galium odoratum and the concentration of coumarin in the medicine must be no more than 0.001%.
2253	GALIUM PALUSTRE	A, H	
2254	GALIUM VERUM	A, H	
2255	GALL STONE	H	Only for use as an active homoeopathic ingredient.
2256	GALPHIMIA GLAUCA	A, H	
2257	GAMMA-4-DIMETHYL-3-CYCLOHEXENE-1-PROPANOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			1%.
2258	GAMMA-BUTYROLACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2259	GAMMA-CYCLODEXTRIN	E	
2260	GAMMA-DECALACTONE	E	Permitted for use only: (a) in topical medicines for dermal application; and (b) in oral medicines in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
2261	GAMMA-DODECALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2262	GAMMA-HEPTALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2263	GAMMA-HEXALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2264	GAMMA-IONONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2265	GAMMA-LINOLEIC ACID	E	Only for use in topical medicines for dermal

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			application.
2266	GAMMA-LINOLENIC ACID	E	
2267	GAMMA-N-METHYL IONONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2268	GAMMA-NONALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2269	GAMMA-OCTALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2270	GAMMA-TERPINENE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2271	GAMMA-TOCOPHEROL	E	
2272	GAMMA-UNDECALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2273	GAMMA-VALEROLACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2274	GANODERMA LUCIDUM	A, E, H	
2275	GARCINIA GUMMI-GUTTA	A	Only for use in oral medicines. Must be obtained from the rind

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			of the fruit only. Must not contain any directions for use for children or pregnant or lactating women.
2276	GARCINIA QUAESITA	A, H	
2277	GARDEN BEAN	E	
2278	GARDENIA JASMINOIDES	A, E	
2279	GARDENIA TAHITENSIS FLOWER EXTRACT	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.002%
2280	GARLIC BULB DRY	A, E, H	
2281	GARLIC BULB FRESH	A, H	
2282	GARLIC BULB POWDER	A, E, H	
2283	GARLIC CLOVE POWDER	A, H	
2284	GARLIC OIL	A, E, H	
2285	GASTRODIA ELATA	A, H	
2286	GAULTHERIA PROCUMBENS	A, E, H	Methyl salicylate is a mandatory component of Gaultheria procumbens. Not to be included in medicines for use in the eye or on damaged skin. When used internally, the concentration of methyl salicylate in the medicine must not be more than 0.001%. When the concentration of methyl salicylate in a liquid

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			preparation is more than 5% and the dosage form is other than spray, the medicine requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is spray, the medicine does not require child resistant packaging if: - the delivery device is engaged into the container in such a way that prevents it from being readily removed; - direct suction through the delivery device results in delivery of no more than one dosage unit; and - actuation of the spray device is ergonomically difficult for young children to accomplish. In addition, when the ingredient is included in a medicine that is listed in the Register: - on or after 1 July 2018, the medicine must comply with all requirements under (a) & (b); - before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a) & (b); or - before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with the requirements under (a) & (b). a) The following warning

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			statement is required on the medicine label: - (METSAL) 'Contains methyl salicylate' (or words to that effect). b) When for use in topical medicines for dermal application, the concentration of methyl salicylate in the medicine must not be more than 25% and the following warning statements are required on the medicine label: - (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect); - (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less'; - (SENS) 'Application to skin may increase sensitivity to sunlight.' (or words to that effect); - (IRRIT) 'If irritation develops, discontinue use.'; and - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect).
2287	GELATIN	A, E	
2288	GELIDIUM AMANSII	A, H	Iodine is a mandatory component of Gelidium amansii. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2289	GELLAN GUM	E	
2290	GELSEMIUM DRY	A, H	The concentration of Gelsemium dry in the medicine must be no more than 1mg/Kg or 1mg/L or 0.0001%.
2291	GELSEMIUM POWDER	A, H	
2292	GELSEMIUM SEMPERVIRENS	A, H	The concentration of equivalent dry Gelsemium sempervirens in the product must be no more than 1mg/Kg or 1mg/L or 0.0001%.
2293	GENET ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2294	GENTIAN DRY	A, H	
2295	GENTIAN POWDER	A, H	
2296	GENTIANA LUTEA	A, E, H	
2297	GENTIANA MACROPHYLLA	A, H	
2298	GENTIANA RHODANTHA	A, H	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2299	GENTIANA SCABRA	A, H	
2300	GENTIANELLA AMARELLA	A, H	
2301	GERANIAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2302	GERANIC ACID	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2303	GERANIOL	E	Permitted for use only: (a) in topical medicines for dermal application; and (b) in oral medicines in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
2304	GERANIUM	E	Permitted for use only in combination with other permitted ingredients as a fragrance.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2305	GERANIUM MACULATUM	A, E, H	
2306	GERANIUM OIL	A, E, H	
2307	GERANIUM OIL SAPONIFIED	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2308	GERANIUM OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2309	GERANIUM ROBERTIANUM	A, E, H	
2310	GERANIUM ROSE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2311	GERANIUM SIBIRICUM	A, E, H	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2312	GERANYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2313	GERANYL ACETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2314	GERANYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2315	GERANYL CROTONATE	E	Permitted for use only in combination with other permitted ingredients as a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2316	GERANYL ETHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2317	GERANYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2318	GERANYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2319	GERANYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2320	GERANYL NITRILE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2321	GERANYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2322	GERANYL TIGLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			fragrance concentration in a medicine must be no more than 1%.
2323	GEUM RIVALE	A, H	
2324	GEUM URBANUM	A, H	
2325	GHATTI GUM	A, E, H	
2326	GIGARTINA MAMILLOSA	A, H	Iodine is a mandatory component of Gigartina mamillosa. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2327	GINGER DRY	A, E, H	
2328	GINGER OIL	A, E, H	
2329	GINGER OLEORESIN	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in the medicine must be no more than 5%.
2330	GINGER POWDER	A, E, H	
2331	GINKGO BILOBA	A, E, H	The Ginkgo biloba leaf extract used in the manufacture of this

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27), as in force or existing from time to time. This condition does not apply to powdered or dried leaf.
2332	GLACIAL ACETIC ACID	E, H	The concentration in the medicine must be no more than 1.5%.
2333	GLECHOMA HEDERACEA	A, H	
2334	GLECHOMA LONGITUBA	A, H	
2335	GLEDITSIA AUSTRALIS	A, H	
2336	GLEDITSIA SINENSIS	A, H	
2337	GLEHNIA LITTORALIS	A, H	
2338	GLORIOSA SUPERBA	A, H	Colchicine is a mandatory component of Gloriosa superba and must be declared in the application. The concentration of colchicine in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
2339	GLUCOMANNAN	E	Only for use when the dosage form is other than tablet.
2340	GLUCONOLACTONE	E	
2341	GLUCOSAMINE HYDROCHLORIDE	A, E	When derived from seafood, the medicine requires the following warning statement

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			on the medicine label: - (SFOOD) 'Derived from seafood'.
2342	GLUCOSAMINE SULFATE	A	When derived from seafood, the medicine requires the following warning statement on the medicine label: - (SFOOD) 'Derived from seafood'.
2343	GLUCOSAMINE SULFATE POTASSIUM CHLORIDE	A	Potassium chloride is a mandatory component of glucosamine sulfate potassium chloride. When derived from seafood, the medicine requires the following warning statement on the medicine label: - (SFOOD) 'Derived from seafood'. When for oral use, the medicine requires the following warning statement on the medicine label: - (POTAS) ‘Contains [amount of potassium in milligrams] mg of potassium. If you have kidney disease or are taking heart or blood pressure medicines - consult your doctor or pharmacist before use. Keep out of reach of children.’
2344	GLUCOSAMINE SULFATE SODIUM CHLORIDE	A	When derived from seafood, the medicine requires the following warning statement on the medicine label: - (SFOOD) 'Derived from

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			seafood'.
2345	GLUCOSE	A, E, H	When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label: - (LACT) ‘Contains lactose' (or words to that effect).
2346	GLUCOSE GLUTAMATE	E	Only for use in topical medicines for dermal application.
2347	GLUCOSE MONOHYDRATE	A, E, H	When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose monohydrate, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			requires the following warning statement on the medicine label: - (SUGARS) 'Contains [insert name of sugar]' if medicine contains one sugar OR 'Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label: - (LACT) 'Contains lactose' (or words to that effect).
2348	GLUCOSYLRUTIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
2349	GLUTAMIC ACID	A, E	Only for use in topical medicines for dermal application.
2350	GLUTAMIC ACID HYDROCHLORIDE	A, E, H	
2351	GLUTAMINE	A, E, H	
2352	GLUTARAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			flavour concentration in a medicine must be no more than 5%.
2353	GLUTATHIONE	A, E	When used as an active ingredient, glutathione can only be used in medicines with an oral route of administration and must be indicated for use in adults only and not in pregnant or lactating women. The medicine requires the following warning statement on the medicine label: - (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect) - (ADULT) 'Adults only' (or words to that effect).
2354	GLUTEN-FREE WHEAT STARCH	E	
2355	GLYCERETH-26	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 7%.
2356	GLYCEROL	A, E	When used as an active ingredient, it is only for use in topical medicines for dermal application.
2357	GLYCEROL ESTER OF PARTIALLY HYDROGENATED GUM ROSIN	E	Only for use when the dosage form is 'chewing gum'.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			Must comply with: a) the Glycerol Ester of Partially Hydrogenated Gum Rosin monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopoeia or the United States Pharmacopeia-National Formulary, as in force or existing from time to time.
2358	GLYCERYL BEHENATE	E	Behenic acid is a mandatory component of glyceryl behenate. When for oral ingestion, the maximum recommended daily dose must not provide more than 383.5 milligrams of behenic acid. In medicines for topical use, the concentration of glyceryl behenate must be no more than 5%.
2359	GLYCERYL CAPRYLATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
2360	GLYCERYL DIISOSTEARATE	E	For use in topical medicines for

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			dermal application.
2361	GLYCERYL DILAURATE	E	Only for use in topical medicines for dermal application.
2362	GLYCERYL DIOLEATE	E	Only for use in topical medicines for dermal application.
2363	GLYCERYL DISTEARATE	E	Only for use in topical medicines for dermal application.
2364	GLYCERYL GLUCOSIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
2365	GLYCERYL ISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5.5%.
2366	GLYCERYL LAURATE	E	Only for use in topical medicines for dermal application.
2367	GLYCERYL LINOLEATE	E	Only for use in topical medicines for dermal

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			application.
2368	GLYCERYL LINOLENATE	E	Only for use in topical medicines for dermal application.
2369	GLYCERYL MONOOLEATE	E	
2370	GLYCERYL MONOSTEARATE	E	
2371	GLYCERYL MYRISTATE	E	Only for use in topical medicines for dermal application.
2372	GLYCERYL OLEATE CITRATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 4% of the formulation.
2373	GLYCERYL PALMITO-STEARATE	E	
2374	GLYCERYL POLYACRYLATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.15%.
2375	GLYCERYL POLYMETHACRYLATE	E	Only for use in topical medicines for dermal application.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2376	GLYCERYL RICINOLEATE	E	Only for use in topical medicines for dermal application.
2377	GLYCERYL ROSINATE	E	Only for use when the dosage form is 'chewing gum'. Must comply with: a) the Glycerol Ester of Gum Rosin monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopoeia or the United States Pharmacopeia National Formulary, as in force or existing from time to time.
2378	GLYCERYL SORBITAN OLEOSTEARATE	E	Only for use in topical medicines for dermal application.
2379	GLYCERYL STARCH	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 4%. The residual levels of epichlorohydrin are to be kept below the level of detection.
2380	GLYCERYL STEARATE CITRATE	E	Only for use in topical medicines for dermal application. The concentration in the

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine must be no more than 5%.
2381	GLYCERYL TRIACETYL HYDROXYSTEARATE	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 6%.
2382	GLYCERYL TRIACETYL RICINOLEATE	E	Only for use in topical medicines for dermal application.
2383	GLYCERYL TRINITRATE	H	Only for use as an active homoeopathic ingredient.
2384	GLYCERYL UNDECYLENATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration of glyceryl undecylenate in a medicine must be no more than 3%.
2385	GLYCINE	A, E	
2386	GLYCINE MAX	A, E, H	
2387	GLYCOGEN	E	Only for use in topical medicines for dermal application.
2388	GLYCOL DISTEARATE	E	Only for use in topical medicines for dermal application.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2389	GLYCOLIC ACID	E	Only for use in topical medicines for dermal application. Sponsors should consider the impact of excipients on the sensitivity of the skin to sunlight and should ensure the finished product is safe for its intended purpose. When present as an excipient in sunscreens, the concentration in the medicine must be no more than 5%. When used as an excipient ingredient in other medicines the concentration in the medicine must be no more than 20%. If the concentration is more than 5% but no more than 20%, the pH of the medicine must be 3.5 or greater.
2390	GLYCYRRHIZA GLABRA	A, E, H	
2391	GLYCYRRHIZA SPECIES	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2392	GLYCYRRHIZA URALENSIS	A, E, H	
2393	GLYCYRRHIZINIC ACID	E	
2394	GNAPHALIUM AFFINE	A, H	
2395	GNAPHALIUM POLYCEPHALUM	A, H	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2396	GNAPHALIUM ULIGINOSUM	A, H	
2397	GOAT	H	Only for use as an active homoeopathic ingredient.
2398	GOAT MILK	E	If the product is for oral ingestion and contains lactose, then the medicine requires the following warning statement on the medicine label: - (LACT) 'Contains lactose' (or words to that effect).
2399	GOLD	E, H	Only for use as an active homoeopathic or excipient ingredient.
2400	GOLD CHLORIDE	H	Only for use as an active homoeopathic ingredient.
2401	GOLDEN ROD HERB DRY	A, E, H	
2402	GOLDEN SEAL ROOT DRY	A, H	
2403	GOLDEN SEAL ROOT POWDER	A, H	
2404	GOLDEN SYRUP	E	Sucrose is a mandatory component of Golden syrup when the route of administration of the medicine is oral or sublingual. When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			on the medicine label: - (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label: - (LACT) ‘Contains lactose' (or words to that effect).
2405	GOMPHRENA GLOBOSA	A, H	
2406	GOOSEBERRY	E	
2407	GOSSYPIUM HERBACEUM	A, E, H	
2408	GRAPE	E	
2409	GRAPE SEED OIL	E	
2410	GRAPE WINE RED	E	Ethanol is a mandatory component of Grape wine red. When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label: - (ETHAN) ‘Contains ethanol’ or ‘contains alcohol’
2411	GRAPE WINE SHERRY	E	Ethanol is a mandatory component of Grape wine sherry. When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			statement on the medicine label: - (ETHAN) 'Contains ethanol' or 'contains alcohol'
2412	GRAPE WINE WHITE	E	Ethanol is a mandatory component of Grape wine white. When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label: - (ETHAN) 'Contains ethanol' or 'contains alcohol'
2413	GRAPEFRUIT	E	
2414	GRAPEFRUIT OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2415	GRAPEFRUIT OIL COLDPRESSED	A, E, H	
2416	GRAPEFRUIT OIL CONCENTRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine must be no more than 5%.
2417	GRAPEFRUIT OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2418	GRAPEFRUIT OIL TERPENES AND TERPENOIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2419	GRAPHITE	H	Only for use as an active homoeopathic ingredient.
2420	GRATIOLA LINIFOLIA	A, H	
2421	GREATER NETTLE HERB DRY	A, H	
2422	GREATER NETTLE HERB POWDER	A, H	
2423	GREATER NETTLE ROOT DRY	A, H	
2424	GREATER NETTLE ROOT POWDER	A, H	
2425	GREEN LIPPED MUSSEL	A	
2426	GREEN LIPPED MUSSEL DRIED	A	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2427	GREEN LIPPED MUSSEL OIL	A	
2428	GREEN S	E	Only for use as a colour in topical and oral medicines.
2429	GRIFOLA FRONDOSA	A	When the route of administration is oral or sublingual, the medicine requires the following warning statement on the medicine label: -(WARF) 'Do not take while on warfarin therapy without medical advice.'
2430	GRINDELIA CAMPORUM	A, H	
2431	GRINDELIA ROBUSTA	A, H	
2432	GRISALVA	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2433	GROUND IVY HERB DRY	A, H	
2434	GROUND IVY HERB POWDER	A, H	
2435	GUAIAC WOOD OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			fragrance concentration in a medicine must be no more 1%.
2436	GUAIACOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in the medicine must be no more than 5%.
2437	GUAIACUM OFFICINALE	A, E, H	
2438	GUAIACUM RESIN	A, E, H	
2439	GUAIACUM SANCTUM	A, H	
2440	GUAIACWOOD ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2441	GUAIENE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2442	GUAIYL ACETATE	E	Permitted for use only in

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2443	GUANINE	E	Only for use as an excipient in topical medicines for dermal application.
2444	GUANOSINE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 0.01% in the medicine.
2445	GUAR GALACTOMANNAN	A	When for oral use: (a) the maximum daily dose must provide no more than 25 g of guar galactomannan; (b) the medicine requires the following dosage instructions: - (FIBRE) 'The dose of fibre should be increased gradually. Fluid intake should be increased with an increasing dose of fibre.' (or words to that effect) (c) when the dosage form is a powder preparation, the medicine requires the following dosage instructions: - (DNTPOW) 'Do not take powder alone. Mix with food

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			or fluid.' (or words to that effect).
2446	GUAR GUM	A, E, H	
2447	GUAR HYDROXYPROPYLTRIMONIUM CHLORIDE	E	Only for use as an excipient in topical medicines for dermal application.
2448	GUAREA RUSBYI	A, H	
2449	GUAVA	E	
2450	GURJUN BALSAM	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2451	GYMNADENIA NIGRA	A	
2452	GYMNEMA SYLVESTRE	A, H	
2453	GYMNOCLADUS DIOICA	A, H	
2454	GYNOSTEMMA PENTAPHYLLUM	A	The herbal substance must be derived from the aerial parts of the vine only (stem, leaves, fruit).
2455	GYNURA JAPONICA	A, H	
2456	HAHNEMANN'S SOLUBLE MERCURY	H	Only for use as an active homoeopathic ingredient.
2457	HALIBUT-LIVER OIL	A, E	Colecalciferol and Vitamin A are mandatory components of Halibut-liver oil. When for internal use, the

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			maximum recommended daily dose must be no more than 25 micrograms of Vitamin D. When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%. When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents. When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label: - (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use. - (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.' NOTE: Position this warning at the beginning of the directions for use. - (VITA3) 'The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			for women and 900 micrograms retinol equivalents for men.'
2458	HAMAMELIS LEAF DRY	A, H	
2459	HAMAMELIS LEAF POWDER	A, H	
2460	HAMAMELIS VIRGINIANA	A, E, H	
2461	HAMAMELIS WATER	A, E, H	
2462	HANDROANTHUS HEPTAPHYLLUS	A, H	
2463	HANDROANTHUS IMPETIGINOSUS	A, E, H	
2464	HARD FAT	E	
2465	HARD PARAFFIN	E	
2466	HARICOT BEAN	E	
2467	HARPAGOPHYTUM PROCUMBENS	A, E, H	
2468	HARUNGANA MADAGASCARIENSIS	A, H	
2469	HAZEL NUT	E	
2470	HAZEL NUT OIL	E	
2471	HEAVY KAOLIN	E	
2472	HEAVY MAGNESIUM OXIDE	A, E, H	
2473	HECTORITE	E	Only for use in topical medicines for dermal application.
2474	HEDEOMA PULEGIOIDES	A	
2475	HEDERA HELIX	A, H	Emetine is a mandatory component of Hedera helix. The concentration of emetine in the medicine must be no

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			more than 0.2%.
2476	HEDTA	E	Only for use as an excipient in topical medicines for dermal application.
2477	HEKLA LAVA	H	Only for use as an active homoeopathic ingredient.
2478	HELESTRALIS	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2479	HELIANTHEMUM NUMMULARIUM	A, H	
2480	HELIANTHUS ANNUUS	A, E, H	
2481	HELIANTHUS TUBEROSUS	A, H	
2482	HELICHRYSUM ANGUSTIFOLIUM	A, E, H	
2483	HELICHRYSUM ARENARIUM	A, H	
2484	HELIOTROPYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2485	HELLEBORUS NIGER	A, H	The maximum recommended daily dose must be no more

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			than 1mg of the equivalent dry herbal material.
2486	HELLEBORUS VIRIDIS	A, H	The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material.
2487	HELONIAS RHIZOME DRY	A, H	
2488	HELONIAS RHIZOME POWDER	A, H	
2489	HEMIDESMUS INDICUS	A, E, H	
2490	HEPTANAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2491	HEPTANAL DIMETHYL ACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2492	HEPTANOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2493	HEPTENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2494	HEPTYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2495	HEPTYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2496	HEPTYL UNDECYLENATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			on damaged skin. The concentration of the medicine must be no more than 25%.
2497	HERACLEUM HEMSLEYANUM	A, H	
2498	HERNIARIA GLABRA	A, H	
2499	HESPERIDIN	A, E	
2500	HEX-3-ENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2501	HEXAHYDRO-4,7-METHANOINDEN-6-YL PIVALATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2502	HEXAMETHYLINDANOPYRAN	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2503	HEXAN-1-OL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2504	HEXANE	E	The concentration of the medicine must be no more than 0.029%. When used for a route of administration other than topical, the residual solvent limit for Hexane is 2.9 mg per recommended daily dose.
2505	HEXANOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2506	HEXANOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2507	HEXASODIUM FYTATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration of Hexasodium fytate in the medicine must be no more than 1.0 %.
2508	HEXENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2509	HEXYL 2-METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2510	HEXYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2511	HEXYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2512	HEXYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2513	HEXYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2514	HEXYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2515	HEXYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2516	HEXYL LAURATE	E	Only for use as an excipient in topical medicines for dermal application.
2517	HEXYL NICOTINATE	E	
2518	HEXYL PROPIONATE	E	Only for use in medicines in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must not be more than 5%.
2519	HEXYL SALICYLATE	E	Permitted for use only in combination with other permitted ingredients as a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2520	HEXYL TIGLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2521	HEXYLDECANOL	E	Only for use as an excipient in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration of the medicine must be no more than 3%.
2522	HEXYLENE GLYCOL	E	Only for use as an excipient in topical medicines for dermal application.
2523	HEXYLRESORCINOL	A	Permitted for use only in medicated throat lozenges. The medicine of must not contain more than 2.5 mg of hexylresorcinol per lozenge. The maximum recommended daily dose of the medicine must not provide more than 30mg of hexylresorcinol. The medicine label must

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			specify that the medicine is only to be used for 7 days (or less). The following warning statement must be included on the medicine label: - (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect).
2524	HIBISCUS ESCULENTUS	A, H	
2525	HIBISCUS MUTABILIS	A, H	
2526	HIBISCUS ROSA-SINENSIS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2527	HIBISCUS SABDARIFFA	A, E, H	
2528	HIERACIUM PILOSELLA	A, H	
2529	HIGH AMYLOSE MAIZE STARCH	A, E, H	
2530	HIGH CHROMIUM YEAST	A, E	Chromium is a mandatory component of high chromium yeast. The maximum recommended daily dose must not provide more than 50 micrograms of chromium from organic chromium sources. High chromium yeast is considered to be an organic form of chromium.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2531	HIGH FRUCTOSE MAIZE SYRUP	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2532	HIGH MOLYBDENUM YEAST	A, E	Molybdenum is a mandatory component of high molybdenum yeast. The maximum daily dose of molybdenum from high molybdenum yeast must be no more than 62.5 micrograms.
2533	HIGH SELENIUM YEAST	A	When for oral or sublingual use, selenium is a mandatory component of high selenium yeast. Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose. When for oral use, the medicine requires the following warning statement on the medicine label: - (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'
2534	HIMATANTHUS LANCIFOLIUS	A, E, H	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2535	HIPPOPHAE RHAMNOIDES	A, E, H	
2536	HIRSCHFELDIA INCANA	A, H	Allyl isothiocyanate is a mandatory component of Hirschfeldia incana when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
2537	HISTAMINE DIHYDROCHLORIDE	H	Only for use as an active homoeopathic ingredient.
2538	HISTIDINE	A	
2539	HISTIDINE HYDROCHLORIDE	A, E, H	
2540	HO LEAF OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2541	HO WOOD OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine must be no more 1%.
2542	HOLCUS LANATUS	A, H	
2543	HOLY THISTLE HERB DRY	A, H	
2544	HOLY THISTLE HERB POWDER	A, H	
2545	HOMALOMENA OCCULTA	A, H	
2546	HOMOSALATE	A, E	For use as an active ingredient only in sunscreens for dermal application. For use as an excipient only in topical medicines for dermal application. Not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 15%. When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect). When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			label if supplied after 1 July 2019: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
2547	HONEY	A, E	When the route of administration is oral, the medicine requires the following warning statement on the medicine label: - (BABY2) 'Not suitable for infants under the age of twelve months' (or words to that effect). When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			label: - (LACT) ‘Contains lactose' (or words to that effect).
2548	HONEY BEE	H	Only for use as an active homoeopathic ingredient.
2549	HONEY EXTRACT	E	Not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%. When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars.
2550	HONEY POWDER	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2551	HOP STROBILE DRY	A, H	
2552	HOP STROBILE POWDER	A, H	
2553	HOPS OIL	A, E, H	
2554	HORDEUM DISTICHON	A, E, H	Gluten is a mandatory component when the plant part is seed, and must be declared in the application when the route of administration is other than topical and mucosal.
2555	HORDEUM VULGARE	A, E, H	Gluten is a mandatory component when the plant part is seed, and must be declared in the application when the route of administration is other than topical and mucosal.
2556	HOREHOUND EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2557	HORSE RADISH	E, H	Volatile oil components (of Armoracia rusticana) is a mandatory component of Horse radish. The maximum recommended daily dose must be no more than 20 mg of volatile oil components (of Armoracia rusticana).

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2558	HOTTONIA PALUSTRIS	A, H	
2559	HOUTTUYNIA CORDATA	A, H	
2560	HOVENIA DULCIS	A, H	
2561	HUMULUS LUPULUS	A, E, H	
2562	HYALURONIC ACID	E	Only for use as an excipient in topical medicines for dermal application.
2563	HYDNOCARPUS ANTHELMINTICA	A, H	When the medicine is for other than topical use and the plant part is seed, the maximum recommended daily dose must be no more than 1mg of the equivalent dry seed.
2564	HYDRANGEA ARBORESCENS	A, H	
2565	HYDRANGEA PANICULATA	A, H	
2566	HYDRASTIS CANADENSIS	A, E, H	
2567	HYDRATED SILICA	E	Only for use when the route of administration is other than inhalation.
2568	HYDROCHLORIC ACID	E	The concentration of the medicine must be no more than 0.5%.
2569	HYDROCOTYLE UMBELLATA	A, H	
2570	HYDROFLUORIC ACID	H	Only for use as an active homoeopathic ingredient.
2571	HYDROGEN CYANIDE	H	Only for use as an active homoeopathic ingredient.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2572	HYDROGEN PEROXIDE	A, E	When used as the active ingredient, it is only for use in topical medicines for dermal application. The concentration of hydrogen peroxide in the medicine must be no more than 3%. When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
2573	HYDROGENATED BUTYLENE/ETHYLENE/STYRENE COPOLYMER	E	Only for use in topical medicines for dermal application. The combined concentration of hydrogenated butylene/ethylene/stryene copolymer and hydrogenated ethylene/propylene/styrene copolymer in the medicine must be no more than 9%.
2574	HYDROGENATED C6-14 OLEFIN POLYMERS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 7%.
2575	HYDROGENATED CASTOR OIL	E	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2576	HYDROGENATED COCO-GLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.
2577	HYDROGENATED COCONUT OIL	E	
2578	HYDROGENATED COTTONSEED OIL	E	
2579	HYDROGENATED DIMER DILINOLEYL/DIMETHYLCARBONATE COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 4% in the product.
2580	HYDROGENATED ETHYLENE/PROPYLENE/STYRENE COPOLYMER	E	The combined concentration of hydrogenated ethylene/propylene/styrene copolymer must be no more than 9%.
2581	HYDROGENATED LANOLIN	E	
2582	HYDROGENATED LECITHIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2583	HYDROGENATED PALM GLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1.6%.
2584	HYDROGENATED PALM GLYCERIDES CITRATE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.01%.
2585	HYDROGENATED PALM KERNEL OIL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1.2%.
2586	HYDROGENATED PALM OIL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%. Polycyclic aromatic hydrocarbons must be kept below the level of detection.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2587	HYDROGENATED POLYDECENE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
2588	HYDROGENATED POLYISOBUTENE	E	Only for use in topical medicines for dermal application.
2589	HYDROGENATED SOYA OIL	E	
2590	HYDROGENATED TALLOW GLYCERIDE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.
2591	HYDROGENATED VEGETABLE OIL	E	
2592	HYDROLIAC	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2593	HYDROLYSED ADANSONIA DIGITATA LEAF POLYSACCHARIDES	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			The concentration in the medicine must be no more than 0.01%
2594	HYDROLYSED ALGIN	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.02%
2595	HYDROLYSED CEREAL SOLIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2596	HYDROLYSED COLLAGEN	A, E	
2597	HYDROLYSED ELASTIN	E	Only for use in topical medicines for dermal application.
2598	HYDROLYSED GELATIN	A, E	
2599	HYDROLYSED GLYCOSAMINOGLYCANS	E	Only for use in topical medicines for dermal application.
2600	HYDROLYSED JOJOBA ESTERS	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine must be no more than 5%.
2601	HYDROLYSED KERATIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
2602	HYDROLYSED MAIZE STARCH	E	
2603	HYDROLYSED MILK PROTEIN	E	
2604	HYDROLYSED RICE	A, E, H	
2605	HYDROLYSED RICE PROTEIN	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.125%.
2606	HYDROLYSED SOY PROTEIN	E	Only for use in topical medicines for dermal application not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.5%.
2607	HYDROLYSED VEGETABLE PROTEIN	E	
2608	HYDROLYSED WHEAT PROTEIN	E	When the route of administration is other than

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			topical or mucosal, the medicine requires the following warning statement on the medicine label: - (GLUTEN) 'Contains [insert name of ingredient]' or words to that effect.
2609	HYDROLYSED WHEAT PROTEIN/PVP CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 1.2%.
2610	HYDROLYSED YEAST PROTEIN	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.3%.
2611	HYDROQUINONE DIMETHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2612	HYDROUS WOOL FAT	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
2613	HYDROXOCOBALAMIN	A	
2614	HYDROXYACETOPHENONE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 1%.
2615	HYDROXYAPATITE	A, E	
2616	HYDROXYCITRATE COMPLEX	A	Hydroxycitrate complex must contain one or more of the three salts (calcium, sodium or potassium hydroxycitrate) of hydroxycitric acid.
2617	HYDROXYCITRIC ACID	A	
2618	HYDROXYCITRONELLAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2619	HYDROXYCITRONELLAL DIMETHYL ACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2620	HYDROXYCITRONELLAL-METHYLANTHRANILATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2621	HYDROXYCITRONELLOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2622	HYDROXYETHYL CETEARAMIDOPROPYLDIMONI	E	Only for use in topical medicines for dermal

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
	UM CHLORIDE		application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
2623	HYDROXYETHYL UREA	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 1%.
2624	HYDROXYLATED LANOLIN	E	
2625	HYDROXYLATED MILK GLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 0.1%.
2626	HYDROXYLYSINE	A, E	
2627	HYDROXYMETHYLCELLULOSE	E	
2628	HYDROXYOCTACOSANYL HYDROXYSTEARATE	E	Only for use in topical medicines for dermal application.
2629	HYDROXYPALMITOYL SPHINGANINE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration must be no

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			more than 0.1%.
2630	HYDROXYPROLINE	A, E	
2631	HYDROXYPROPYL DISTARCH PHOSPHATE	E	Only permitted for: - use in topical medicines for dermal application; and - medicines for internal use. When for use in topical medicines for dermal application: - not to be included medicines intended for use in the eye or damaged skin; and - the concentration of hydroxypropyl distarch phosphate in the medicine must be no more than 4%. When for internal use, the maximum recommended daily dose must not contain more than 240mg of hydroxypropyl distarch phosphate.
2632	HYDROXYPROPYL STARCH	E	
2633	HYDROXYPROPYLBETADEX	E	Only for use in topical medicines for dermal application.
2634	HYDROXYSTEARIC ACID	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 9%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2635	HYETELLOSE	E	
2636	HYLOCEREUS LEMAIREI	E	Permitted for use only as a colour for oral and topical use.
2637	HYLOCEREUS UNDATUS	A, H	
2638	HYMETELLOSE	E	
2639	HYOSCYAMUS LEAF DRY	A, H	Alkaloids calculated as hyoscyamine and hyoscine are mandatory components of Hyoscamus leaf dry. The concentration of alkaloids calculated as hyoscyamine in the medicine must be no more than 300 micrograms/Kg or 300 micrograms/L or 0.00003%. The concentration of hyoscine in the medicine must be no more than than 300 micrograms/kg or 300 micrograms/L or 0.00003%.
2640	HYOSCYAMUS LEAF POWDER	A, H	Alkaloids calculated as hyoscyamine and hyoscine are mandatory components of Hyoscamus leaf powder. The concentration of alkaloids calculated as hyoscyamine in the medicine must be no more than 300 micrograms/Kg or 300 micrograms/L or 0.00003%. The concentration of hyoscine in the medicine must be no more than 300 micrograms/kg or 300 micrograms/L or 0.00003%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2641	HYOSCYAMUS NIGER	A, H	Alkaloids calculated as hyoscyamine and hyoscine are mandatory components of Hyoscyamus niger. The concentration of hyoscyamine in the medicine must be no more than 3 micrograms/kg or 3 micrograms/L or 0.3%. The concentration of hyoscine in the medicine must be no more than 300 micrograms/kg or 300 micrograms/L or 0.00003%.
2642	HYPERICUM ASCYRON	A, H	
2643	HYPERICUM JAPONICUM	A, H	
2644	HYPERICUM PERFORATUM	A, E, H	When used for oral ingestion, the medicine requires the following warning statement on the medicine label: - (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'
2645	HYPROLOSE	E	
2646	HYPROMELLOSE	E	
2647	HYPROMELLOSE PHTHALATE	E	
2648	HYPTIS SUAVEOLENS	A, H	
2649	HYSSOPUS OFFICINALIS	A, E, H	
2650	IBERIS AMARA	A, H	
2651	ICHTHAMMOL	H	Only for use as an active homoeopathic ingredient.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2652	ILEX AQUIFOLIUM	A, H	
2653	ILEX CHINENSIS	A, H	
2654	ILEX PARAGUARIENSIS	A, E, H	Caffeine is a mandatory component of Ilex paraguariensis. When the medicine is packaged for supply as an undivided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 4%. When the medicine is packaged for supply as a divided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 33%. The requirements specified in paragraphs (a) to (e) below apply in relation to a medicine that contains the ingredient that: - is listed in the Register on or after 2 September 2019; or - is supplied after 2 March 2021. A medicine that contains the ingredient and that: - was listed in the Register before 2 September 2019; and - is supplied before 2 March 2021; may comply with the requirements in paragraphs (a) to (e) below. a) When for internal use or oral application, the maximum

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			recommended daily dose of the medicine must provide no more than 400mg of total caffeine. b) When the medicine is packaged for supply as an undivided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 1%. c) When the medicine is for internal use or oral application, a maximum recommended dose of the medicine must not provide more than 100 mg of total caffeine within a 3 hour period. d) When the maximum recommended daily dose of the medicine provides greater than 10 mg of total caffeine and the medicine is for internal use or oral application, the following warning statements are required on the label: - (ADULT) 'Adults only' (or words to that effect). - (CAFF) 'Contains [state quantity per dosage unit or per mL or per gram of product] total caffeine [per dosage unit or per mL or per gram]. A cup of instant coffee contains approximately 80mg of caffeine.' - (CAFFPREG) ‘Caffeine intake more than 200 mg per day is not recommended during pregnancy or breastfeeding.’ e) When the maximum recommended daily dose of the

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine provides greater than 80 mg of total caffeine and the medicines is for internal use or oral application, the following warning statements are required on the label: - (CAFFLMT) 'Limit the use of caffeine-containing products (including tea and coffee) when taking this product.' - (CAFFCYP) 'Caffeine interacts with enzyme CYP1A2 in the liver. Consult your health professional before taking with other medicines' (or words to that effect).
2655	ILEX ROTUNDA	A, H	
2656	ILEX VERTICILLATA	A, H	
2657	ILLICIUM VERUM	A, H	When the plant preparation is oil or distillate, the nominal capacity of the container must be no more than 50 millilitres. When the concentration of Illicium verum oil or distillate in the preparation is greater than 50%, a restricted flow insert must be fitted on the container and the medicine must include the following warning statement on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
2658	IMIDUREA	E	Only for use in topical medicines for dermal

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			application.
2659	IMMORTELLE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2660	IMMORTELLE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2661	IMPATIENS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2662	IMPATIENS BALSAMINA	A, H	
2663	IMPATIENS GLANDULIFERA	A, H	
2664	IMPERATA CYLINDRICA	A, E, H	
2665	INDIGO CARMINE	E	Permitted for use only as a colour for oral and topical use.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2666	INDIGO CARMINE ALUMINIUM LAKE	E	Permitted for use only as a colour for oral and topical use.
2667	INDIGOFERA TINCTORIA	A, H	
2668	INDISAN	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2669	INDOLE	E, H	Only for use as an active homoeopathic or excipient ingredient. The maximum recommended daily dose must contain no more than 75 mg indole.
2670	INDOLENE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2671	INDUSTRIAL METHYLATED SPIRIT	E	
2672	INOSITOL	A, E	
2673	INULA BRITANNICA	A, H	
2674	INULA HELENIUM	A, E, H	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2675	INULA RACEMOSA	A, H	
2676	INULIN	A, E	
2677	INULIN LAURYL CARBAMATE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. The concentration in the medicine must be no more than 1.2%.
2678	INVERT SUGAR	E	When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100 mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label: - (LACT) ‘Contains lactose' (or words to that effect).
2679	INVERT SYRUP	E	Glucose is a mandatory component of Invert syrup when the route of administration is oral or

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			sublingual. When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100 mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label: - (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars. If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label: - (LACT) ‘Contains lactose' (or words to that effect).
2680	IODINE	H	Only for use as an active homoeopathic ingredient. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2681	IODOPROPYNYL BUTYLCARBAMATE	E	For use as an excipient ingredient in topical medicines only. The concentration in aqueous medicines must be no more than 10%.
2682	IONONE	E	Permitted for use only: (a) in topical medicines for dermal application; and (b) in oral medicines in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
2683	IOPAMIDOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2684	IPECACUANHA DRY	A, H	Emetine is a mandatory component of Ipecacuanha Dry. The concentration of emetine in the medicine must be no more than 0.2%.
2685	IPECACUANHA POWDER	A, H	Emetine is a mandatory component of Ipecacuanha

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			Powder. The concentration of emetine in the medicine must be no more than 0.2%.
2686	IPECACUANHA PREPARED	A, H	Emetine is a mandatory component of Ipecacuanha Prepared. The concentration of emetine in the medicine must be no more than 0.2%.
2687	IPECACUANHA ROOT LIQUID EXTRACT	A, H	Emetine is a mandatory component of Ipecacuanha root liquid extract. The concentration of emetine in the medicine must be no more than 0.2%.
2688	IPOMOEA BATATAS	A, H	
2689	IPOMOEA JALAPA	A, H	
2690	IRIDOPHYCUS FLACCIDUM	A, H	Iodine is a mandatory component of Iridophycus flaccidum. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is more than 2.5%. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2691	IRIS DOMESTICA	A, H	
2692	IRIS FLORENTINA	A, H	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2693	IRIS GERMANICA	A, H	
2694	IRIS PALLIDA	A, H	
2695	IRIS TENAX	H	
2696	IRIS VERSICOLOR	A, H	
2697	IRON	A, H	Only for use in oral medicines. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2698	IRON (II) BISGLYCINE SULFATE TRIHYDRATE	A	Only for use in oral medicines. Iron is a mandatory component of iron (II) bisglycine sulfate trihydrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2699	IRON (II) GLYCINATE	A	Only for use in oral medicines. Iron is a mandatory component of iron (II) glycinate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2700	IRON (III) GLYCINATE	A	Only for use in oral medicines. Iron is a mandatory component of iron (III) glycinate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			effect). When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2701	IRON AMINO ACID CHELATE	A, H	Only for use in oral medicines. When used internally, iron is a mandatory component of iron amino acid chelate. The concentration of iron in iron amino acid chelate must be no more than 25%. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2702	IRON OXIDE BLACK	E	Permitted for use only as a colour for oral and topical use. When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided preparations for internal use, the concentration in the medicine must be no more than 10 mg per dosage unit.
2703	IRON OXIDE RED	E	Permitted for use only as a colour for oral and topical use. When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided preparations for internal use, the concentration in the medicine must be no more than 10 mg per dosage unit.
2704	IRON OXIDE YELLOW	E	Permitted for use only as a colour for oral and topical use.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided preparations for internal use, the concentration in the medicine must be no more than 10 mg per dosage unit.
2705	IRON PHOSPHATE	A, E, H	When used internally, iron is a mandatory component of iron phosphate and must be declared. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register on or after 1 October 2017 the medicine must have the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims and the medicine is listed in the Register before 1 October 2017 the medicine requires the following statement on the medicine label if supplied after 1 April 2019: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2706	IRONE	E	
2707	IRVINGIA GABONENSIS SEED TRIGLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 0.375%.
2708	ISATIS TINCTORIA	A, H	
2709	ISOAMBRETTOLIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2710	ISOAMYL 2-METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2711	ISOAMYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2712	ISOAMYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2713	ISOAMYL BENZOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2714	ISOAMYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine must be no more 1%.
2715	ISOAMYL CAPRYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2716	ISOAMYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2717	ISOAMYL CITRONELLYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2718	ISOAMYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2719	ISOAMYL HEXANOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2720	ISOAMYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2721	ISOAMYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2722	ISOAMYL LAURATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 12%.
2723	ISOAMYL METHOXYCINNAMATE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%. When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect). When used in primary sunscreen products and listed in the Register before 1

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
2724	ISOAMYL PHENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2725	ISOAMYL PHENYLETHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
2726	ISOAMYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2727	ISOAMYL SALICYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2728	ISOBERGAMIATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2729	ISOBORNEOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			fragrance concentration in a medicine must be no more 1%.
2730	ISOBORNYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2731	ISOBORNYL CYCLOHEXANOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2732	ISOBUTANE	E	Only for use in topical medicines for dermal application.
2733	ISOBUTYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2734	ISOBUTYL ALCOHOL	E	The residual solvent limit for Isobutyl alcohol is 50mg per recommended daily dose. The concentration of isobutyl alcohol must be no more than 0.5% of the formulation.
2735	ISOBUTYL BENZOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
2736	ISOBUTYL BENZYL CARBINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
2737	ISOBUTYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2738	ISOBUTYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2739	ISOBUTYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2740	ISOBUTYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2741	ISOBUTYL HYDROXYBENZOATE	E	Only for use in topical medicines for dermal application. Medicines containing hydroxybenzoates require the following warning statement on the medicine label: - (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			hydroxybenzoate source.
2742	ISOBUTYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2743	ISOBUTYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2744	ISOBUTYL PHENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2745	ISOBUTYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2746	ISOBUTYL QUINOLINE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2747	ISOBUTYL SALICYLATE	E	Only for use in topical medicines for dermal application.
2748	ISOBUTYLENE/ISOPRENE COPOLYMER	E	Only for oral use when the dosage form is chewing gum. The concentration must be consistent with best practice for the production of gum delivery systems.
2749	ISOBUTYRALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2750	ISOBUTYRIC ACID	E	Permitted for use only in combination with other permitted ingredients as a

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2751	ISOCETYL ALCOHOL	E	Only for use in topical medicines for dermal application.
2752	ISOCETYL LINOLEOYL STEARATE	E	Only for use in topical medicines for dermal application.
2753	ISOCETYL STEARATE	E	Only for use in topical medicines for dermal application.
2754	ISOCETYL STEAROYL STEARATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 10%.
2755	ISOCYCLOCITRAL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2756	ISODECYL ISONONANOATE	E	Only for use in topical medicines for dermal application.
2757	ISODECYL NEOPENTANOATE	E	Only for use in topical medicines for dermal application.
2758	ISODECYL OLEATE	E	Only for use in topical medicines for dermal application.
2759	ISODECYL SALICYLATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 2%.
2760	ISODODECANE	E	Only for use in topical medicines for dermal application.
2761	ISOEICOSANE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 2%.
2762	ISOEUGENOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2763	ISOEUGENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2764	ISOEUGENYL BENZYL ETHER	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2765	ISOHEXADECANE	E	Only for use in topical medicines for dermal application.
2766	ISOJASMONE	E	Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation or fragrance proprietary excipient

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			formulation. The total flavour proprietary excipient formulation in a medicine must not be more than 5%. The total fragrance proprietary excipient formulation in a medicine must not be more 1%.
2767	ISOLEUCINE	A, E	
2768	ISOMALT	E	When the quantity of sugar alcohols per maximum recommended daily dose is more than 2g, the quantity of the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label: - (SUGOLS) 'Products containing [insert name of sugar alcohol(s) may have a laxative effect or cause diarrhoea [or words to that effect]'.
2769	ISOMENTHONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2770	ISOMETHYLIONONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2771	ISONONYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2772	ISONONYL ISONONANOATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration must be no more than 15%.
2773	ISOPENTANE	E	For dental use only. The concentration must be no more than 2%.
2774	ISOPENTANOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2775	ISOPHORONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2776	ISOPHYTOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2777	ISOPROPYL 2-METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2778	ISOPROPYL 4-	E	Only for use in topical

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
	HYDROXYBENZOATE		medicines for dermal application. Medicines containing hydroxybenzoates require the following warning statement on the medicine label: - (TOTBNZ) 'Contains hydroxybenzoates' (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR 'Contains [insert the approved name of hydroxybenzoate used]' (or words to this effect) if product contains one hydroxybenzoate source.
2779	ISOPROPYL ACETATE	E	Only for use in topical medicines for dermal application.
2780	ISOPROPYL ALCOHOL	E	
2781	ISOPROPYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2782	ISOPROPYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2783	ISOPROPYL ISOSTEARATE	E	Only for use in topical medicines for dermal application.
2784	ISOPROPYL LANOLATE	E	Only for use in topical medicines for dermal application.
2785	ISOPROPYL LAUROYL SARCOSINATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 5.6%.
2786	ISOPROPYL MYRISTATE	E	
2787	ISOPROPYL PALMITATE	E	Only for use in topical medicines for dermal application.
2788	ISOPROPYL PPG-2 ISODECETH-7 CARBOXYLATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 10%.
2789	ISOPROPYL STEARATE	E	Only for use in topical medicines for dermal application.
2790	ISOPROPYL TITANIUM TRIISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			included in medicines intended for use in the eye. The concentration must be no more than 0.2%.
2791	ISOPROPYL-3-METHYL-BUTANE THIOATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2792	ISOPULEGOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2793	ISORALDEINE 70	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2794	ISOSTEARIC ACID	E	Only for use in topical medicines for dermal application.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2795	ISOSTEAROYL HYDROLYSED COLLAGEN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration must be no more than 0.3%.
2796	ISOSTEARYL ALCOHOL	E	Only for use in topical medicines for dermal application.
2797	ISOSTEARYL NEOPENTANOATE	E	Only for use in topical medicines for dermal application.
2798	ISOSTEARYL PALMITATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration must be no more than 2%.
2799	ISOTRIDECYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2800	ISOVALERALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2801	ISOVALERIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2802	ISPAGHULA HUSK DRY	A, H	When a dose for children is stated, the medicine requires the following warning statement on the medicine label: - (PSYLL) 'On medical advice' (or words to that effect).
2803	ISPAGHULA HUSK POWDER	A, H	When a dose for children is stated, the medicine requires the following warning statement on the medicine label: - (PSYLL) 'On medical advice' (or words to that effect).
2804	IVA AXILLARIS	A, H	
2805	JAMAICA DOGWOOD BARK	A, H	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
	DRY		
2806	JAMAICA DOGWOOD BARK POWDER	A, H	
2807	JASMINE ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2808	JASMINE LACTONE	E	Only for use in topical medicines for dermal application.
2809	JASMINE OIL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2810	JASMINUM GRANDIFLORUM	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2811	JASMINUM OFFICINALE	A, E, H	

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
2812	JASSOLIA	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2813	JATEORHIZA PALMATA	A, H	
2814	JATROPHA CURCAS	H	Only for use as an active homoeopathic ingredient
2815	JERUSALEM ARTICHOKE	E	
2816	JOJOBA ESTERS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 25%.
2817	JUGLANS CINEREA	A, E, H	
2818	JUGLANS NIGRA	A, E, H	
2819	JUGLANS REGIA	A, H	
2820	JUNCUS EFFUSUS	A, H	
2821	JUNIPER BERRY OIL	A, E, H	
2822	JUNIPER BERRY OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient name**	**Purpose**	**Specific requirements**
			1%.
2823	JUNIPERUS CALIFORNICA	A, H	
2824	JUNIPERUS COMMUNIS	A, E, H	
2825	JUNIPERUS MEXICANA	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2826	JUNIPERUS OXYCEDRUS	A, H	
2827	JUNIPERUS VIRGINIANA	A, E, H	
2828	JUSTICIA ADHATODA	A, H	